MeiraGTx Holdings plc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−2.24%
vs ±34.0% implied · ×0.07
shaded = implied · ▲▼ = realized
MeiraGTx has 4 disclosed suppliers and 4 disclosed customers in SEC filings.
MeiraGTx Holdings plc
9.45
SentenceIn May 2013, BRI-Alzan Inc., or BRI-Alzan, entered into a license agreement with Brandeis, or the Brandeis Agreement.
MGTX 10-Kaccession 0001104659-26-036494
SentenceCertain of our issued patents and pending patent applications are exclusively licensed to us from UCLB, Brandeis University ("Brandeis") and the National Institute of Dental and Craniofacial Research ("NIDCR").
MGTX 10-Kaccession 0001104659-26-036494
SentenceCertain of our issued patents and pending patent applications are exclusively licensed to us from UCLB, Brandeis University ("Brandeis") and the National Institute of Dental and Craniofacial Research ("NIDCR").
MGTX 10-Kaccession 0001104659-26-036494
SentenceAdditionally, in December 2025, we entered into an agreement with ZipBio, a biotechnology company pioneering AI-driven protein therapeutics, which granted MeiraGTx an exclusive license to several proprietary AI-designed complement inhibitors.
MGTX 10-Kaccession 0001104659-26-036494
SentenceMeiraGTx UK II Limited and Johnson & Johnson Innovative Medicine also entered into a Supply Agreement on the Closing Date pursuant to which MeiraGTx UK II Limited agreed to manufacture and supply the RPGR Product for Johnson & Johnson Innovative Medicine (the "Supply Agreement").
SentenceOn November 7, 2025 (the "Effective Date"), our affiliates MeiraGTx Ocular UK Limited ("MeiraGTx Ocular"), MeiraGTx Limited and MeiraGTx UK II Limited, entered into a strategic collaboration and license agreement with Eli Lilly and Company ("Lilly") (the "Lilly Collaboration Agreement") for the research, development and commercialization of genetic medicines in and related to the area of ophthalmology.
SentenceHologen will also contribute a portion of the annual funding to MeiraGTx Manufacturing.
MGTX 10-Kaccession 0001104659-26-036494
SentenceIn October 2023, we announced that under the terms of the Investment Agreement (the "Investment Agreement") we entered into with Sanofi Foreign Participations B.V. ("Sanofi Foreign Participations"), a wholly-owned subsidiary of Sanofi, and solely for the limited purposes set forth therein, Sanofi, Sanofi has a right of first negotiation for use of our riboswitch gene regulation technology for certain Immunology and Inflammation (I&I), including modulation of IL-4 and IL-13, and Central Nervous System (CNS) targets, as well as for GLP-1 and other gut peptides for metabolic disease, and for our Phase 2 xerostomia program.
MGTX 10-Kaccession 0001104659-26-036494
Linked news
Expected move
Inputs8Q avg ±6.4%·×6.88·rich
straddle ±44.8%
spot 9.49exp Nov 20ATM strike 10ATM straddle 5.00IV 272%